Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; ...

Neurovation Labs Joins NewYorkBIO Fellows Program to Accelerate Development of Biomarker-Driven Neuromedicines and Diagnostics

Company to attend upcoming NewYorkBIO Innovation Summit on September 30, 2025, in New York City NEW YORK CITY, NY / ACCESS ...

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will ...

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and ...
Medscape

Navigating Symptom Burden in Breast Cancer: Approaches to Common Adverse Effects of Treatment

From fatigue to neuropathy, managing treatment-related side effects is central to improving quality of life in breast cancer.
Taiwan News

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction ...

- SP16 has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat CIPN, synergistically complementing Halneuron®, the Company’s late stage NaV1.7 inhibitor, ...